New York, June 9, 2026, 10:05 EDT
Nuvalent surged Tuesday after GSK said it would buy the Nasdaq-listed biotech for $10.6 billion, or $124 a share in cash. The stock shot up 38.9% to $122.93, almost reaching the offer price and trading like the day’s standard merger-arb play.
That wasn’t a full biotech sector rally. The SPDR S&P Biotech ETF climbed 2.1%, while the iShares Nasdaq Biotechnology ETF put on 1.4%. Nuvalent’s pop looked like a move on its own news, not a general sector rebound.
Nuvalent’s deal is in focus now as its top two lung-cancer drugs, zidesamtinib and neladalkib, sit with the U.S. Food and Drug Administration. The FDA has target decision dates set for Sept. 18 and Nov. 27. Both drugs target non-small cell lung cancer, the most common form, with ROS1 and ALK gene changes providing clear targets for therapies.
GSK said it plans to launch a tender offer in the next 10 business days, asking Nuvalent shareholders to sell their stock straight to the company. The offer values Nuvalent at a 40% premium to its last close, and 26% above its 30-day VWAP, which factors both price and volume.
GSK Chief Executive Luke Miels described the buy as a “multi-product deal” and said the two main drugs could become “significant new treatment options” if regulators give the green light. Nuvalent CEO James Porter said GSK’s reach would help get zidesamtinib and neladalkib to market and back what he called “practice-changing innovation.” Nuvalent Investors
Miels told reporters the deal is outside GSK’s normal range, calling it “unusual” and “essentially three products in one.” James Eugene, analyst at Verso Investment Management, said some investors may have been caught off guard by the size, as many expected GSK to stick with deals worth $2 billion to $4 billion. Reuters
GSK is looking for more heft in oncology, where cancer drugs are still a small part of its business. Reuters said that last year, oncology made up just 6% of GSK’s total sales, compared to AstraZeneca’s 44% from cancer drugs. GSK’s U.S. shares were flat early in New York.
Nuvalent saw a quick round of analyst moves after the deal. H.C. Wainwright downgraded the stock to neutral from buy and slashed its target to $124 from $155. Wells Fargo also shifted to equal weight from overweight and pushed its target up to $124 from $116, according to MarketScreener, which cited MT Newswires.
An SEC filing said the deal isn’t subject to a financing condition. Still, it needs more than half of Nuvalent’s Class A shares to be tendered and has to get approval under the Hart-Scott-Rodino Act, which is a U.S. antitrust review. Affiliates of Deerfield Management and some Nuvalent directors and officers, together holding about 28% of Class A, have agreed to tender their shares.
GSK won’t be alone if neladalkib clears regulators and hits the market. Pfizer’s Lorbrena and Roche’s Alecensa are already ALK-targeting competitors, Reuters reported, naming them as drugs GSK will have to go up against.
The trade isn’t without risk. If the FDA holds up approval or the label is narrower than expected, Nuvalent’s drug value could take a hit. The deal might also drag on if tender, antitrust, or other closing conditions get in the way. A break-up could cost Nuvalent $350.475 million in a termination fee to GSK, according to an SEC filing.
Right now, Nuvalent shares are sticking near the cash offer, not trading above it. That doesn’t leave much room for upside without a new suitor stepping in. The small spread left is mostly about timing, regulatory sign-off, and whether the deal will actually close.
Related articles: Biotechnology
